MIRM · Insider Trading
Mirum Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by MIRM officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-04 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | −$1.74M |
| 2026-10-19 | Jolanda Howe | SVP, GLOBAL CONTROLLER | M | +16,112 | +$309.99K |
| 2026-10-14 | Robert Paul Myers | Chief Medical Officer | A | +65,000 deriv. | — |
| 2026-10-06 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | M | +12,197 | +$211.18K |
| 2026-09-15 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | MIXED | +8,390 | −$978.09K |
| 2026-09-03 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | −658 | −$65.80K |
| 2026-09-03 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | −$2.87M |
| 2026-08-19 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | — | −$3.75M |
| 2026-08-12 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Sell | −6,001 | −$599.51K |
| 2026-08-11 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | −$1.92M |
| 2026-08-05 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | −1,840 | −$193.73K |
| 2026-07-08 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | −$2.39M |
| 2026-07-08 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | Sell | −5,000 | −$611.27K |
| 2026-07-02 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | −2,721 | −$326.52K |
| 2026-06-18 | Jolanda Howe | SVP, GLOBAL CONTROLLER | Sell | −2,594 | −$264.46K |
| 2026-06-17 | Patrick J Heron | Director | A | +5,752 deriv. | — |
| 2026-06-17 | Laurent Fischer | Director | A | +5,752 deriv. | — |
| 2026-06-17 | Laura Brege | Director | A | +5,752 deriv. | — |
| 2026-06-17 | William Fairey | Director | A | +5,752 deriv. | — |
| 2026-06-17 | Timothy P Walbert | Director | A | +5,752 deriv. | — |
| 2026-06-17 | Lon Cardon | Director | A | +5,752 deriv. | — |
| 2026-06-17 | Saira Ramasastry | Director | A | +5,752 deriv. | — |
| 2026-06-17 | Michael G Grey | Director | A | +5,752 deriv. | — |
| 2026-06-09 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | MIXED | −2,607 | −$405.69K |
| 2026-06-08 | Peter Radovich | PRESIDENT AND COO | M | +16,988 | +$326.00K |
| 2026-06-02 | Lon Cardon | Director | M | +3,977 | — |
| 2026-06-02 | Timothy P Walbert | Director | M | +3,977 | — |
| 2026-06-02 | Saira Ramasastry | Director | MIXED | — | −$397.70K |
| 2026-06-02 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | — | −$2.79M |
| 2026-06-02 | Laurent Fischer | Director | M | +3,977 | — |
| 2026-05-18 | Saira Ramasastry | Director | MIXED | — | −$171.92K |
| 2026-04-16 | Saira Ramasastry | Director | MIXED | — | −$146.78K |
| 2026-03-17 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | MIXED | +6,047 | −$670.24K |
| 2026-03-17 | Saira Ramasastry | Director | MIXED | — | −$134.50K |
| 2026-03-17 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | +34,015 | −$3.77M |
| 2026-03-17 | Peter Radovich | PRESIDENT AND COO | MIXED | +13,705 | −$1.52M |
| 2026-03-17 | Joanne Quan | CHIEF MEDICAL OFFICER | MIXED | +6,047 | −$670.24K |
| 2026-03-17 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | +3,926 | −$435.24K |
| 2026-03-11 | Peter Radovich | PRESIDENT AND COO | M | +5,912 | +$93.82K |
| 2026-02-17 | Saira Ramasastry | Director | MIXED | — | −$157.16K |
| 2026-02-03 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | Sell | −9,108 | −$940.89K |
| 2026-02-03 | Peter Radovich | PRESIDENT AND COO | Sell | −2,631 | −$271.79K |
| 2026-02-03 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | +803 | −$100.00K |
| 2026-01-30 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | A | +185,500 deriv. | — |
| 2026-01-30 | Eric Bjerkholt | CHIEF FINANCIAL OFFICER | A | +49,900 deriv. | — |
| 2026-01-30 | Joanne Quan | CHIEF MEDICAL OFFICER | A | +49,900 deriv. | — |
| 2026-01-30 | Peter Radovich | PRESIDENT AND COO | A | +75,900 deriv. | — |
| 2026-01-30 | Jolanda Howe | SVP, GLOBAL CONTROLLER | A | +21,650 deriv. | — |
| 2026-01-27 | Christopher Peetz | CHIEF EXECUTIVE OFFICER | MIXED | +5,669 | −$657.09K |
| 2026-01-27 | Jolanda Howe | SVP, GLOBAL CONTROLLER | MIXED | +658 | −$80.99K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Patrick J Heron | Director | 464,713 | $43.12M |
| Christopher Peetz | CHIEF EXECUTIVE OFFICER | 394,137 | $36.57M |
| Michael G Grey | Director | 93,750 | $8.70M |
| Peter Radovich | PRESIDENT AND COO | 57,260 | $5.31M |
| Eric Bjerkholt | CHIEF FINANCIAL OFFICER | 44,745 | $4.15M |
| Joanne Quan | CHIEF MEDICAL OFFICER | 26,151 | $2.43M |
| Jolanda Howe | SVP, GLOBAL CONTROLLER | 16,728 | $1.55M |
| Laura Brege | Director | 15,703 | $1.46M |
| Laurent Fischer | Director | 10,727 | $995.36K |
| Timothy P Walbert | Director | 9,680 | $898.21K |
| Lon Cardon | Director | 9,680 | $898.21K |
| Saira Ramasastry | Director | 3,977 | $369.03K |
| William Fairey | Director | 2,500 | $231.98K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the MIRM quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.